MX2016004841A - Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk). - Google Patents
Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).Info
- Publication number
- MX2016004841A MX2016004841A MX2016004841A MX2016004841A MX2016004841A MX 2016004841 A MX2016004841 A MX 2016004841A MX 2016004841 A MX2016004841 A MX 2016004841A MX 2016004841 A MX2016004841 A MX 2016004841A MX 2016004841 A MX2016004841 A MX 2016004841A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidine compounds
- substituted pyrimidine
- syk inhibitors
- formula
- methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000000551 Syk Kinase Human genes 0.000 abstract 1
- 108010016672 Syk Kinase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención describe compuestos de la fórmula (I) y métodos para la inhibición de las cinasas, incluyendo las tirosinas cinasas del bazo. También se describen métodos para el tratamiento de una enfermedad a afección mediada por una cinasa, por la administración a un sujeto de una cantidad terapéuticamente efectiva del compuesto de la fórmula (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893866P | 2013-10-21 | 2013-10-21 | |
| PCT/US2014/061649 WO2015061369A1 (en) | 2013-10-21 | 2014-10-21 | Substituted pyrimidine compounds and their use as syk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004841A true MX2016004841A (es) | 2016-07-26 |
| MX376059B MX376059B (es) | 2025-03-07 |
Family
ID=52826699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004841A MX376059B (es) | 2013-10-21 | 2014-10-21 | Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk). |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9212178B2 (es) |
| EP (1) | EP3060562B1 (es) |
| JP (1) | JP6434506B2 (es) |
| KR (1) | KR102228034B1 (es) |
| CN (1) | CN105940000B (es) |
| AU (1) | AU2014340249B2 (es) |
| CL (1) | CL2016000939A1 (es) |
| EA (1) | EA030962B1 (es) |
| ES (1) | ES2890552T3 (es) |
| HU (1) | HUE056048T2 (es) |
| IL (1) | IL244817B (es) |
| MX (1) | MX376059B (es) |
| MY (1) | MY184561A (es) |
| NZ (1) | NZ718576A (es) |
| PH (1) | PH12016500735B1 (es) |
| PL (1) | PL3060562T3 (es) |
| PT (1) | PT3060562T (es) |
| SA (1) | SA516370989B1 (es) |
| SG (1) | SG11201602566XA (es) |
| WO (1) | WO2015061369A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113248472B (zh) * | 2020-02-12 | 2022-06-28 | 中国药科大学 | 抗骨质疏松化合物及其衍生物，药物组合物、制备方法和应用 |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| US20240285621A1 (en) * | 2020-09-23 | 2024-08-29 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| AU2024259993A1 (en) * | 2023-04-24 | 2025-11-06 | Foshan Ionova Biotherapeutics Co., Inc. | Cdk2 inhibitors and methods of using same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| EP1558753A2 (en) | 2002-10-16 | 2005-08-03 | Millennium Pharmaceuticals, Inc. | Spleen tyrosine kinase catalytic domain: crystal structure and binding pockets thereof |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| PL378221A1 (pl) * | 2003-01-17 | 2006-03-20 | Astrazeneca Ab | Tienopirydazynony i ich zastosowanie w modulacji choroby autoimmunologicznej |
| EA200800664A1 (ru) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | Производные пирролопиримидина в качестве ингибиторов syk |
| AU2008296479A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| WO2010015518A2 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
| CA2780892C (en) * | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| KR20120125267A (ko) | 2010-01-29 | 2012-11-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 나프티리딘 및 ｓｙｋ 키나제 억제제로서의 이의 용도 |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| JP2013529204A (ja) | 2010-05-20 | 2013-07-18 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロ［２，３−ｂ］ピラジン−７−カルボキサミド誘導体とＪＡＫ及びＳＹＫ及び阻害剤としてのそれらの使用 |
| WO2011156698A2 (en) * | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| PL2804861T3 (pl) * | 2012-01-20 | 2018-08-31 | Genosco | Podstawione związki pirymidyny i ich zastosowanie jako inhibitory SYK |
| JP6101341B2 (ja) * | 2012-03-22 | 2017-03-22 | オスコテック, インコーポレーテッドOscotec, Inc. | 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用 |
-
2014
- 2014-10-21 EP EP14856054.3A patent/EP3060562B1/en active Active
- 2014-10-21 AU AU2014340249A patent/AU2014340249B2/en active Active
- 2014-10-21 SG SG11201602566XA patent/SG11201602566XA/en unknown
- 2014-10-21 JP JP2016525001A patent/JP6434506B2/ja active Active
- 2014-10-21 WO PCT/US2014/061649 patent/WO2015061369A1/en not_active Ceased
- 2014-10-21 EA EA201690818A patent/EA030962B1/ru not_active IP Right Cessation
- 2014-10-21 US US14/520,279 patent/US9212178B2/en active Active
- 2014-10-21 CN CN201480065838.7A patent/CN105940000B/zh active Active
- 2014-10-21 PL PL14856054T patent/PL3060562T3/pl unknown
- 2014-10-21 MY MYPI2016701436A patent/MY184561A/en unknown
- 2014-10-21 PT PT148560543T patent/PT3060562T/pt unknown
- 2014-10-21 NZ NZ71857614A patent/NZ718576A/en unknown
- 2014-10-21 MX MX2016004841A patent/MX376059B/es active IP Right Grant
- 2014-10-21 PH PH1/2016/500735A patent/PH12016500735B1/en unknown
- 2014-10-21 ES ES14856054T patent/ES2890552T3/es active Active
- 2014-10-21 HU HUE14856054A patent/HUE056048T2/hu unknown
- 2014-10-21 KR KR1020167013308A patent/KR102228034B1/ko active Active
-
2016
- 2016-03-29 IL IL244817A patent/IL244817B/en active IP Right Grant
- 2016-04-20 CL CL2016000939A patent/CL2016000939A1/es unknown
- 2016-04-20 SA SA516370989A patent/SA516370989B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3060562T (pt) | 2021-09-02 |
| CN105940000B (zh) | 2019-12-24 |
| AU2014340249A1 (en) | 2016-04-28 |
| EP3060562B1 (en) | 2021-07-28 |
| US9212178B2 (en) | 2015-12-15 |
| CL2016000939A1 (es) | 2016-11-11 |
| IL244817B (en) | 2019-07-31 |
| WO2015061369A1 (en) | 2015-04-30 |
| US20150111883A1 (en) | 2015-04-23 |
| SG11201602566XA (en) | 2016-05-30 |
| PH12016500735B1 (en) | 2022-04-29 |
| HUE056048T2 (hu) | 2022-01-28 |
| EP3060562A4 (en) | 2017-06-14 |
| MY184561A (en) | 2021-04-03 |
| KR102228034B1 (ko) | 2021-03-16 |
| MX376059B (es) | 2025-03-07 |
| AU2014340249B2 (en) | 2017-05-25 |
| EP3060562A1 (en) | 2016-08-31 |
| JP2016534054A (ja) | 2016-11-04 |
| ES2890552T3 (es) | 2022-01-20 |
| JP6434506B2 (ja) | 2018-12-05 |
| IL244817A0 (en) | 2016-05-31 |
| EA201690818A1 (ru) | 2016-08-31 |
| PL3060562T3 (pl) | 2022-01-10 |
| PH12016500735A1 (en) | 2016-05-30 |
| EA030962B1 (ru) | 2018-10-31 |
| CN105940000A (zh) | 2016-09-14 |
| KR20160068967A (ko) | 2016-06-15 |
| NZ718576A (en) | 2019-11-29 |
| HK1226395A1 (zh) | 2017-09-29 |
| BR112016008060A8 (pt) | 2020-03-17 |
| SA516370989B1 (ar) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| GT201600123A (es) | Inhibidores de syk | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| EA201690268A1 (ru) | Замещенные производные хиназолин-4-она | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| MX373786B (es) | Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer. | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2020004506A (es) | Derivados del bipirazol como inhibidores de janus cinasa (jak). | |
| MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
| CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
| EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
| MX2016004841A (es) | Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk). | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| EA201790209A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde | |
| NI201500176A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |